Merrill D. Benson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Merrill D. Benson has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Masahide Yazaki
Indiana University School of Medicine and the Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, USA
10 shared publicationsJuris J. Liepnieks
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA, and
9 shared publicationsKamran Hamidi Asl
Indiana University School of Medicine and the Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, USA
6 shared publicationsNoel R. Dasgupta
Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, United States; Division of Cardiology, Indiana University School of Medicine, Indianapolis, IN, United States
6 shared publicationsJohn C. Kincaid
4 shared publicationsTaro Yamashita
Indiana University School of Medicine, Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis 46202-5126, USA
4 shared publications
Latest Publications
- 1 January 2021
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 31 (1) , 67-68
Editorial Commentary: Advances in transthyretin amyloid cardiomyopathy
- 1 January 2021
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 31 (1) , 67-68
Editorial Commentary: Advances in transthyretin amyloid cardiomyopathy
- 29 March 2019
- Published by Taylor & Francis in Amyloid
- Vol. 26 (sup1) , 27-28
Inotersen treatment for ATTR amyloidosis
(2019). Inotersen treatment for ATTR amyloidosis. Amyloid: Vol. 26, Proceedings of the XVI International Symposium on Amyloidosis Kumamoto, Japan 26-29 March 2018, pp. 27-28.
- 29 March 2019
- Published by Taylor & Francis in Amyloid
- Vol. 26 (sup1) , 27-28
Inotersen treatment for ATTR amyloidosis
(2019). Inotersen treatment for ATTR amyloidosis. Amyloid: Vol. 26, Proceedings of the XVI International Symposium on Amyloidosis Kumamoto, Japan 26-29 March 2018, pp. 27-28.
- 29 March 2019
- Published by Taylor & Francis in Amyloid
- Vol. 26 (sup1) , 20-21
Treatment of ATTR cardiomyopathy with a TTR specific antisense oligonucleotide, inotersen
(2019). Treatment of ATTR cardiomyopathy with a TTR specific antisense oligonucleotide, inotersen. Amyloid: Vol. 26, Proceedings of the XVI International Symposium on Amyloidosis Kumamoto, Japan 26-29 March 2018, pp. 20-21.
- 29 March 2019
- Published by Taylor & Francis in Amyloid
- Vol. 26 (sup1) , 20-21
Treatment of ATTR cardiomyopathy with a TTR specific antisense oligonucleotide, inotersen
(2019). Treatment of ATTR cardiomyopathy with a TTR specific antisense oligonucleotide, inotersen. Amyloid: Vol. 26, Proceedings of the XVI International Symposium on Amyloidosis Kumamoto, Japan 26-29 March 2018, pp. 20-21.
- 18 December 2018
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 9 (1) , 25-30
Inotersen ( Transthyretin -Specific Antisense Oligonucleotide) for Treatment of Transthyretin Amyloidosis
Hereditary transthyretin amyloidosis (ATTR) is a fatal systemic disease that results from deposition of the misfolded protein transthyretin (TTR) in tissues. Common clinical manifestations of ATTR include peripheral neuropathy, cardiomyopathy, autonomic dysfunction, diarrhea and constipation. Historically there have not been effective therapies for this devastating disease. Inotersen/Tegsedi™ (Akcea Therapeutics, MA, USA) is a second-generation antisense oligonucleotide (ASO) specific for TTR that inhibits production of TTR by the liver. In the recently completed Phase III NEURO-TTR study, inotersen was shown to be effective in stabilizing or improving peripheral neuropathy as measured by the modified neurologic impairment score +7 (mNIS+7) and improving the quality of life assessed by the Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) questionnaire. Inotersen is a breakthrough therapy for treatment of ATTR.
- 18 December 2018
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 9 (1) , 25-30
Inotersen ( Transthyretin -Specific Antisense Oligonucleotide) for Treatment of Transthyretin Amyloidosis
Hereditary transthyretin amyloidosis (ATTR) is a fatal systemic disease that results from deposition of the misfolded protein transthyretin (TTR) in tissues. Common clinical manifestations of ATTR include peripheral neuropathy, cardiomyopathy, autonomic dysfunction, diarrhea and constipation. Historically there have not been effective therapies for this devastating disease. Inotersen/Tegsedi™ (Akcea Therapeutics, MA, USA) is a second-generation antisense oligonucleotide (ASO) specific for TTR that inhibits production of TTR by the liver. In the recently completed Phase III NEURO-TTR study, inotersen was shown to be effective in stabilizing or improving peripheral neuropathy as measured by the modified neurologic impairment score +7 (mNIS+7) and improving the quality of life assessed by the Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) questionnaire. Inotersen is a breakthrough therapy for treatment of ATTR.
- Open Access
Exploring Mechanisms of Inhibition of Amyloid Seeding of Transthyretin
Amyloid deposition of the hormone transporter transthyretin causes familial and sporadic amyloidoses. The current treatment for familial cases is gene-therapy by liver transplantation. However, this procedure is often insufficient to stop subsequent cardiac deposition. Our recent work has shown that preformed amyloid fibrils present in the heart by the time of surgery can template or seed further polymerization of native transthyretin. No drugs have been approved to stop or slow this seeding process; the only treatment option is heart transplantation. Here we explore two potential inhibitory mechanisms. Of clinical significance, we found that tetramer stabilization does not hinder amyloid seeding. In contrast, binding of the peptide inhibitor TabFH2 to ex-vivo fibrils efficiently inhibits amyloid seeding in a tissue-independent manner. Our findings point to inhibition of amyloid seeding by peptide inhibitors as a potential therapeutic approach to be further explored.
Open AccessExploring Mechanisms of Inhibition of Amyloid Seeding of Transthyretin
Amyloid deposition of the hormone transporter transthyretin causes familial and sporadic amyloidoses. The current treatment for familial cases is gene-therapy by liver transplantation. However, this procedure is often insufficient to stop subsequent cardiac deposition. Our recent work has shown that preformed amyloid fibrils present in the heart by the time of surgery can template or seed further polymerization of native transthyretin. No drugs have been approved to stop or slow this seeding process; the only treatment option is heart transplantation. Here we explore two potential inhibitory mechanisms. Of clinical significance, we found that tetramer stabilization does not hinder amyloid seeding. In contrast, binding of the peptide inhibitor TabFH2 to ex-vivo fibrils efficiently inhibits amyloid seeding in a tissue-independent manner. Our findings point to inhibition of amyloid seeding by peptide inhibitors as a potential therapeutic approach to be further explored.
- 14 September 2017
- Published by Taylor & Francis in Amyloid
- Vol. 24 (4) , 217-223
Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy
Objectives: Cardiomyopathy is a major cause of death in both the hereditary form of transthyretin (TTR) amyloidosis and the sporadic late-age-onset transthyretin amyloidosis (ATTR wild-type (ATTRwt)). Clinically disease progression from time of diagnosis to death is usually quoted as 5- to 15-years. In prior studies, significant progression of cardiac parameters in patients with moderate to severe cardiomyopathy has been noted within a 12-month time span. Methods: The present study was designed to prospectively monitor changes in cardiac parameters, both structural and functional, in patients with ATTR cardiomyopathy while treated with a TTR specific antisense oligonucleotide (ASO; IONIS-TTR℞) designed to lower blood levels of the amyloid fibril precursor protein. To date 22 patients have been admitted to the study, 15 have completed 12 months on the drug and are the subject of this report. Results: Eight patients with hereditary ATTR amyloidosis and 7 patients with wild-type ATTR amyloidosis with moderate to severely advanced restrictive cardiomyopathy showed stabilization of disease as measured by left ventricular wall thickness, left ventricular mass (LVM), 6-min walk test (6MWT), and echocardiographic global systolic strain. IONIS-TTR℞ was well tolerated by all 15 subjects and showed a good safety profile. Conclusions: ASO treatment of patients with moderate to advanced ATTR cardiomyopathy shows indication of stabilization of disease progression and may therefore contribute to enhanced life expectancy.
- 14 September 2017
- Published by Taylor & Francis in Amyloid
- Vol. 24 (4) , 217-223
Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy
Objectives: Cardiomyopathy is a major cause of death in both the hereditary form of transthyretin (TTR) amyloidosis and the sporadic late-age-onset transthyretin amyloidosis (ATTR wild-type (ATTRwt)). Clinically disease progression from time of diagnosis to death is usually quoted as 5- to 15-years. In prior studies, significant progression of cardiac parameters in patients with moderate to severe cardiomyopathy has been noted within a 12-month time span. Methods: The present study was designed to prospectively monitor changes in cardiac parameters, both structural and functional, in patients with ATTR cardiomyopathy while treated with a TTR specific antisense oligonucleotide (ASO; IONIS-TTR℞) designed to lower blood levels of the amyloid fibril precursor protein. To date 22 patients have been admitted to the study, 15 have completed 12 months on the drug and are the subject of this report. Results: Eight patients with hereditary ATTR amyloidosis and 7 patients with wild-type ATTR amyloidosis with moderate to severely advanced restrictive cardiomyopathy showed stabilization of disease as measured by left ventricular wall thickness, left ventricular mass (LVM), 6-min walk test (6MWT), and echocardiographic global systolic strain. IONIS-TTR℞ was well tolerated by all 15 subjects and showed a good safety profile. Conclusions: ASO treatment of patients with moderate to advanced ATTR cardiomyopathy shows indication of stabilization of disease progression and may therefore contribute to enhanced life expectancy.
- 16 March 2017
- Published by Taylor & Francis in Amyloid
- Vol. 24 (sup1) , 76-77
Transthyretin amyloidosis: a little history of hereditary amyloidosis
(2017). Transthyretin amyloidosis: a little history of hereditary amyloidosis. Amyloid: Vol. 24, PROCEEDINGS OF THE XVth INTERNATIONAL SYMPOSIUM ON AMYLOIDOSIS, pp. 76-77.
- 16 March 2017
- Published by Taylor & Francis in Amyloid
- Vol. 24 (sup1) , 76-77
Transthyretin amyloidosis: a little history of hereditary amyloidosis
(2017). Transthyretin amyloidosis: a little history of hereditary amyloidosis. Amyloid: Vol. 24, PROCEEDINGS OF THE XVth INTERNATIONAL SYMPOSIUM ON AMYLOIDOSIS, pp. 76-77.
- 16 March 2017
- Published by Taylor & Francis in Amyloid
- Vol. 24 (sup1) , 91-92
Familial wild-type transthyretin cardiomyopathy
- 16 March 2017
- Published by Taylor & Francis in Amyloid
- Vol. 24 (sup1) , 91-92
Familial wild-type transthyretin cardiomyopathy
- 16 March 2017
- Published by Taylor & Francis in Amyloid
- Vol. 24 (sup1) , 159-160
Insulin: a diagnostic warning
- 16 March 2017
- Published by Taylor & Francis in Amyloid
- Vol. 24 (sup1) , 159-160
Insulin: a diagnostic warning